Cargando…
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors
The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fus...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390617/ https://www.ncbi.nlm.nih.gov/pubmed/37300720 http://dx.doi.org/10.1007/s10147-023-02360-8 |
_version_ | 1785082516744437760 |
---|---|
author | Mishima, Saori Naito, Yoichi Akagi, Kiwamu Hayashi, Naomi Hirasawa, Akira Hishiki, Tomoro Igarashi, Ataru Ikeda, Masafumi Kadowaki, Shigenori Kajiyama, Hiroaki Kato, Motohiro Kenmotsu, Hirotsugu Kodera, Yasuhiro Komine, Keigo Koyama, Takafumi Maeda, Osamu Miyachi, Mitsuru Nishihara, Hiroshi Nishiyama, Hiroyuki Ohga, Shouichi Okamoto, Wataru Oki, Eiji Ono, Shigeru Sanada, Masashi Sekine, Ikuo Takano, Tadao Tao, Kayoko Terashima, Keita Tsuchihara, Katsuya Yatabe, Yasushi Yoshino, Takayuki Baba, Eishi |
author_facet | Mishima, Saori Naito, Yoichi Akagi, Kiwamu Hayashi, Naomi Hirasawa, Akira Hishiki, Tomoro Igarashi, Ataru Ikeda, Masafumi Kadowaki, Shigenori Kajiyama, Hiroaki Kato, Motohiro Kenmotsu, Hirotsugu Kodera, Yasuhiro Komine, Keigo Koyama, Takafumi Maeda, Osamu Miyachi, Mitsuru Nishihara, Hiroshi Nishiyama, Hiroyuki Ohga, Shouichi Okamoto, Wataru Oki, Eiji Ono, Shigeru Sanada, Masashi Sekine, Ikuo Takano, Tadao Tao, Kayoko Terashima, Keita Tsuchihara, Katsuya Yatabe, Yasushi Yoshino, Takayuki Baba, Eishi |
author_sort | Mishima, Saori |
collection | PubMed |
description | The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy. |
format | Online Article Text |
id | pubmed-10390617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-103906172023-08-02 Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors Mishima, Saori Naito, Yoichi Akagi, Kiwamu Hayashi, Naomi Hirasawa, Akira Hishiki, Tomoro Igarashi, Ataru Ikeda, Masafumi Kadowaki, Shigenori Kajiyama, Hiroaki Kato, Motohiro Kenmotsu, Hirotsugu Kodera, Yasuhiro Komine, Keigo Koyama, Takafumi Maeda, Osamu Miyachi, Mitsuru Nishihara, Hiroshi Nishiyama, Hiroyuki Ohga, Shouichi Okamoto, Wataru Oki, Eiji Ono, Shigeru Sanada, Masashi Sekine, Ikuo Takano, Tadao Tao, Kayoko Terashima, Keita Tsuchihara, Katsuya Yatabe, Yasushi Yoshino, Takayuki Baba, Eishi Int J Clin Oncol Special Article The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy. Springer Nature Singapore 2023-06-10 2023 /pmc/articles/PMC10390617/ /pubmed/37300720 http://dx.doi.org/10.1007/s10147-023-02360-8 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Special Article Mishima, Saori Naito, Yoichi Akagi, Kiwamu Hayashi, Naomi Hirasawa, Akira Hishiki, Tomoro Igarashi, Ataru Ikeda, Masafumi Kadowaki, Shigenori Kajiyama, Hiroaki Kato, Motohiro Kenmotsu, Hirotsugu Kodera, Yasuhiro Komine, Keigo Koyama, Takafumi Maeda, Osamu Miyachi, Mitsuru Nishihara, Hiroshi Nishiyama, Hiroyuki Ohga, Shouichi Okamoto, Wataru Oki, Eiji Ono, Shigeru Sanada, Masashi Sekine, Ikuo Takano, Tadao Tao, Kayoko Terashima, Keita Tsuchihara, Katsuya Yatabe, Yasushi Yoshino, Takayuki Baba, Eishi Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title | Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title_full | Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title_fullStr | Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title_full_unstemmed | Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title_short | Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
title_sort | japanese society of medical oncology/japan society of clinical oncology/japanese society of pediatric hematology/oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390617/ https://www.ncbi.nlm.nih.gov/pubmed/37300720 http://dx.doi.org/10.1007/s10147-023-02360-8 |
work_keys_str_mv | AT mishimasaori japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT naitoyoichi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT akagikiwamu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT hayashinaomi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT hirasawaakira japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT hishikitomoro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT igarashiataru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT ikedamasafumi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT kadowakishigenori japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT kajiyamahiroaki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT katomotohiro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT kenmotsuhirotsugu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT koderayasuhiro japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT kominekeigo japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT koyamatakafumi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT maedaosamu japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT miyachimitsuru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT nishiharahiroshi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT nishiyamahiroyuki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT ohgashouichi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT okamotowataru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT okieiji japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT onoshigeru japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT sanadamasashi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT sekineikuo japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT takanotadao japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT taokayoko japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT terashimakeita japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT tsuchiharakatsuya japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT yatabeyasushi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT yoshinotakayuki japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors AT babaeishi japanesesocietyofmedicaloncologyjapansocietyofclinicaloncologyjapanesesocietyofpediatrichematologyoncologyledclinicalrecommendationsonthediagnosisanduseofimmunotherapyinpatientswithhightumormutationalburdentumors |